Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Grupo Espanol de Tumores Neuroendocrinos
M.D. Anderson Cancer Center
Columbia University
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Advanced Accelerator Applications
Alliance for Clinical Trials in Oncology
Enterome
Advanced Accelerator Applications
University of Washington
Eli Lilly and Company
National Cancer Institute (NCI)